Drug Detail

Information about Ibrance

Generic Name	Palbociclib
IND	PD-0332991
Brand Name (US)	Ibrance
Manufacturer	Pfizer
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	Breast cancer
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	Cdk4 & Cdk6 inhibitor

Palbociclib is a potent and selective inhibitor of Cdk4/cyclin D1 kinase and Cdk6.
Alterations in CDKN2A have been described in GIST. CDKN2A signaling is dependent on Cdk4 and Cdk6 represents an alternate pathway to Cdk4. Thus, it is hypothesized that inhibiting Cdk4 might be an effective strategy against GIST. A clinical trial, NCT01907607 is planned to test this therapy in GIST.